Department of Medicine, University of California and Veterans Affairs San Diego Healthcare System, San Diego, California 92161, USA.
Am J Physiol Renal Physiol. 2013 Jan 15;304(2):F137-44. doi: 10.1152/ajprenal.00064.2012. Epub 2012 Sep 26.
The incretin hormone glucagon-like peptide-1 (GLP-1) is released from the gut in response to fat or carbohydrate and contributes to negative feedback control of blood glucose by stimulating insulin secretion, inhibiting glucagon, and slowing gastric emptying. GLP-1 receptors (GLP-1R) are also expressed in the proximal tubule, and possibly elsewhere in the kidney. Presently, we examined the effect of a GLP-1R agonist on single-nephron glomerular filtration rate (GFR; SNGFR), proximal reabsorption (Jprox), tubuloglomerular feedback (TGF) responses, and urine flow rate in hydropenic male Wistar and Wistar-Froemter rats. Micropuncture and whole-kidney data were obtained before and during infusion of the GLP-1 agonist exenatide (1 nmol/h iv). SNGFR and Jprox were measured by late proximal collection at both extremes of TGF activation, which was achieved by perfusing Henle's loop at 0 or 50 nl/min. Primary changes in Jprox were revealed by analysis of covariance for Jprox with SNGFR as a covariate. Effects on TGF activation were determined in a separate set of experiments by comparing early distal and late proximal collections. Exenatide increased SNGFR by 33-50%, suppressed proximal tubular reabsorption by 20-40%, doubled early distal flow rate, and increased urine flow rate sixfold without altering the efficiency of glomerulotubular balance, TGF responsiveness, or the tonic influence of TGF. This implies that exenatide is both a proximal diuretic and a renal vasodilator. Since the natural agonist for the GLP-1R is regulated by intake of fat and carbohydrate, but not by salt or fluid, the control of salt excretion by the GLP-1R system departs from the usual negative-feedback paradigm for regulating salt balance.
肠促胰岛素激素胰高血糖素样肽-1(GLP-1)在进食脂肪或碳水化合物时从肠道中释放出来,通过刺激胰岛素分泌、抑制胰高血糖素和减缓胃排空,对血糖产生负反馈控制。GLP-1 受体(GLP-1R)也在近端小管中表达,并且可能在肾脏的其他部位表达。目前,我们研究了 GLP-1R 激动剂对水负荷雄性 Wistar 和 Wistar-Froemter 大鼠单肾单位肾小球滤过率(SNGFR)、近端重吸收(Jprox)、管球反馈(TGF)反应和尿流量的影响。在静脉输注 GLP-1 激动剂 exenatide(1 nmol/h)前后,通过微穿刺和全肾数据获得。在 TGF 激活的两个极端,通过以 0 或 50 nl/min 的速度灌注 Henle 环来进行近曲小管的晚期收集,来测量 SNGFR 和 Jprox。通过对以 SNGFR 为协变量的 Jprox 的协方差分析来揭示 Jprox 的主要变化。通过比较早期和晚期的近段收集,在另一组实验中确定对 TGF 激活的影响。Exenatide 将 SNGFR 增加 33-50%,将近端肾小管重吸收抑制 20-40%,将早期远端流量增加一倍,将尿流量增加六倍,而不改变肾小球肾小管平衡的效率、TGF 反应性或 TGF 的紧张影响。这意味着 exenatide 既是一种近端利尿剂,也是一种肾血管扩张剂。由于 GLP-1R 的天然激动剂受脂肪和碳水化合物摄入的调节,而不受盐或液体的调节,因此 GLP-1R 系统对盐排泄的控制偏离了调节盐平衡的常用负反馈模式。